Steven Cohen Akero Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 289,106 shares of AKRO stock, worth $6.62 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
289,106
Previous 644,305
55.13%
Holding current value
$6.62 Million
Previous $15 Million
51.46%
% of portfolio
0.02%
Previous 0.04%
Shares
16 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$140 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$124 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$120 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$119 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$112 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.06B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...